Management of common opioid-induced adverse effects

American Family Physician

Volumn 74, Issue 8, 2006, Pages 1347-1354

  Swegle, John M ^a   Logemann, Craig ^b  

^a Mercy Family Medicine Residency Program   (United States)

^b Urbandale Family Physicians   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BISACODYL; CETIRIZINE; CITROMA; DEXAMPHETAMINE; DIPHENHYDRAMINE; DOCUSATE SODIUM; FENTANYL; FEXOFENADINE; HALOPERIDOL; HYDROXYZINE; ISPAGULA; LACTULOSE; LAXATIVE; LORATADINE; MACROGOL 3350; MAGNESIUM CITRATE; MAGNESIUM HYDROXIDE; METHYLCELLULOSE; METHYLPHENIDATE; MORPHINE; NALOXONE; NEUROLEPTIC AGENT; OPIATE; OXYCODONE; POLYCARBOPHIL; POLYCARBOPHIL CALCIUM; PROKINETIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN ANTAGONIST; SODIUM DIHYDROGEN PHOSPHATE; SORBITOL; UNINDEXED DRUG;

CLINICAL TRIAL; CONSTIPATION; DELIRIUM; DRUG DOSE REDUCTION; HUMAN; NAUSEA; PHYSICIAN; PRURITUS; REVIEW; SEDATION; SIDE EFFECT;

ANALGESICS, OPIOID; CENTRAL NERVOUS SYSTEM DISEASES; CONSTIPATION; HUMANS; NAUSEA; PRURITUS;

EID: 33750217480     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain. 5th ed. Glenview, Ill.: American Pain Society, 2003.
2. Bowsell MV, Cole BE, Weiner RS, American Academy of Pain Management. Weiner's Pain Management: A Practical Guide for Clinicians. 7th ed. Boca Raton, Fla.: Taylor & Francis, 2006.
3. Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001;19:2542-54.
4. Cepeda MS, Farrar JT, Baumgarten M, Boston R, Carr DB, Strom BL. Side effects of opioids during short-term administration: effect of age, gender, and race. Clin Pharmacol Ther 2003;74:102-12.
5. Forman WB. Opioid analgesic drugs in the elderly. Clin Geriatr Med 1996;12:489-500.
6. Pleym H, Spigset O, Kharasch ED, Dale O. Gender differences in drug effects: implications for anesthesiologists. Acta Anaesthesiol Scand 2003;47:241-59.
7. McNicol E, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain 2003;4:231-56.
8. Mercadante S. Opioid rotation for cancer pain: rationale and clinical aspects. Cancer 1999;86:1856-66.
9. de Stoutz ND, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995;10:378-84.
10. Hanks F, Cherny NI, Fallon M. Opioid analgesic therapy. In: Doyle D, Hanks G, Cherny N, Calman K, eds. Oxford Textbook of Palliative Medicine. 3rd ed. New York, N.Y.: Oxford University Press, 2004:316-41.
11. Meuser T, Pietruck C, Radbruch L, Stute P, Lehmann KA, Grond S. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 2001;93:247-57.
12. Sussman G, Shurman J, Creed MR, Larsen LS, Ferrer-Brechner T, Noll D, et al. Intravenous ondansetron for the control of opioid-induced nausea and vomiting. International S3AA3013 Study Group. Clin Ther 1999;21:1216-27.
13. Flake ZA, Scalley RG, Bailey AG. Practical selection of antiemetics. Am Fam Physician 2004;69:1169-74.
14. Baldessarini RJ, Tarazi FI. Drugs and the treatment of psychiatric disorders. In: Goodman LS, Hardman JG, Limbird LE, Gilman AG, eds. Goodman & Gilman's the Pharmacologic Basis of Therapeutics. 10th ed. New York, N.Y.: McGraw-Hill, 2001:485-520.
15. Pasricha PJ. Prokinetic agents, antiemetics, and agents used in irritable bowel syndrome. In: Goodman LS, Hardman JG, Limbird LE, Gilman AG, eds. Goodman & Gilman's the Pharmacologic Basis of Therapeutics. 10th ed. New York, N.Y.: McGraw-Hill, 2001:1021-36.
16. Apfel CC, Korttila K, Abdalla M, Kerger H, Turan A, Veder I, et al. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med 2004;350:2441-51.
17. Ferris FD, Kerr IG, Sone M, Marcuzzi M. Transdermal scopolamine use in the control of narcotic-induced nausea. J Pain Symptom Manage 1991;6:389-93.
18. De Luca A, Coupar IM. Insights into opioid action in the intestinal tract. Pharmacol Ther 1996;69:103-15.
19. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001;182(5A suppl):11S-8S.
20. Herndon CM, Jackson KC II, Hallin PA. Management of opioid-induced gastrointestinal effects in patients receiving palliative care. Pharmacotherapy 2002;22:240-50.
21. Canty SL. Constipation as a side effect of opioids. Oncol Nurs Forum 1994;21:739-45.
22. Staats PS, Markowitz J, Schein J. Incidence of constipation associated with long-acting opioid therapy: a comparative study. South Med J 2004;97:129-34.
23. Allan L, Hays H, Jensen NH, de Waroux BL, Bolt M, Donald R, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 2001;322:1154-8.
24. Jafri S, Pasricha PJ. Agents used for diarrhea, constipation, and inflammatory bowel disease; agents used for biliary and pancreatic disease. In: Goodman LS, Hardman JG, Limbird LE, Gilman AG, eds. Goodman & Gilman's the Pharmacologic Basis of Therapeutics. 10th ed. New York, N.Y.: McGraw-Hill, 2001:1037-58.
25. Gan TJ, Ginsberg B, Glass PS, Fortney J, Jhaveri R, Perno R. Opioid-sparing effects of a low-dose infusion of naloxone in patient-administered morphine sulfate. Anesthesiology 1997;87:1075-81.
26. Sartain JB, Barry JJ, Richardson CA, Branagan HC. Effect of combining naloxone and morphine for intravenous patient-controlled analgesia. Anesthesiology 2003;99:148-51.
27. Cepeda MS, Alvarez H, Morales O, Carr DB. Addition of ultralow dose naloxone to postoperative morphine PCA: unchanged analgesia and opioid requirements but decreased incidence of opioid side effects. Pain 2004;107:41-6.
28. Hirayama T, Ishii F, Yago K, Ogata H. Evaluation of the effective drugs for the prevention of nausea and vomiting induced by morphine used for postoperative pain: a quantitative systematic review. Yakugaku Zasshi 2001;121:179-85.
29. Yee JD, Berde CB. Dextroamphetamine or methylphenidate as adjuvants to opioid analgesia for adolescents with cancer. J Pain Symptom Manage 1994;9:122-5.
30. Christo PJ. Opioid effectiveness and side effects in chronic pain. Anesthesiol Clin North Am 2003;21:699-713.
31. Cherny NI. The management of cancer pain. CA Cancer J Clin 2000;50:70-116.
32. Jackson KC, Lipman AG. Drug therapy for delirium in terminally ill patients. Cochrane Database Syst Rev 2004;(2):CD004770.
33. Breitbart W, Marotta R, Platt MM, Weisman H, Derevenco M, Grau C, et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996;153:231-7.
34. Slatkin NE, Rhiner M. Treatment of opiate-related sedation: utility of the cholinesterase inhibitors. J Support Oncol 2003;1:53-63.
35. Bruera E, Strasser F, Shen L, Palmer JL, Willey J, Driver LC, et al. The effect of donepezil on sedation and other symptoms in patients receiving opioids for cancer pain: a pilot study. J Pain Symptom Manage 2003;26:1049-54.
36. Chaney MA. Side effects of intrathecal and epidural opioids. Can J Anaesth 1995;42:891-903.
37. Zylicz Z, Smits C, Krajnik M. Paroxetine for pruritus in advanced cancer. J Pain Symptom Manage 1998;16:121-4.
38. Brown NJ, Roberts LJ. Histamine, bradykinin, and their antagonists. In: Goodman LS, Hardman JG, Limbird LE, Gilman AG, eds. Goodman & Gilman's the Pharmacologic Basis of Therapeutics. 10th ed. New York, N.Y.: McGraw-Hill, 2001:645-67.